BRPI0913989A2 - processo para preparação de derivados de benzoimidazol-2-il pirirmidina - Google Patents

processo para preparação de derivados de benzoimidazol-2-il pirirmidina

Info

Publication number
BRPI0913989A2
BRPI0913989A2 BRPI0913989A BRPI0913989A BRPI0913989A2 BR PI0913989 A2 BRPI0913989 A2 BR PI0913989A2 BR PI0913989 A BRPI0913989 A BR PI0913989A BR PI0913989 A BRPI0913989 A BR PI0913989A BR PI0913989 A2 BRPI0913989 A2 BR PI0913989A2
Authority
BR
Brazil
Prior art keywords
pyrirmidine
benzoimidazol
derivatives
preparing
pyrirmidine derivatives
Prior art date
Application number
BRPI0913989A
Other languages
English (en)
Inventor
Christopher M Mapes
Daniel J Pippel
David C Palmer
Diego Broggini
Jeffrey S Grimm
Neelakandha S Mani
Sergio Cesco-Cancian
Susanne Lochner
Tong Xiao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41426846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913989(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0913989A2 publication Critical patent/BRPI0913989A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0913989A 2008-06-30 2009-06-29 processo para preparação de derivados de benzoimidazol-2-il pirirmidina BRPI0913989A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7675908P 2008-06-30 2008-06-30
PCT/US2009/049033 WO2010002777A2 (en) 2008-06-30 2009-06-29 Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0913989A2 true BRPI0913989A2 (pt) 2015-10-20

Family

ID=41426846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913989A BRPI0913989A2 (pt) 2008-06-30 2009-06-29 processo para preparação de derivados de benzoimidazol-2-il pirirmidina

Country Status (27)

Country Link
US (3) US20100029942A1 (pt)
EP (2) EP2865678A3 (pt)
JP (2) JP2011526911A (pt)
KR (1) KR20110022721A (pt)
CN (2) CN103319459A (pt)
AR (1) AR072397A1 (pt)
AU (1) AU2009267159B2 (pt)
BR (1) BRPI0913989A2 (pt)
CA (1) CA2729703A1 (pt)
CL (1) CL2010001639A1 (pt)
CO (1) CO6341626A2 (pt)
CR (1) CR20110057A (pt)
EA (1) EA020090B1 (pt)
EC (1) ECSP11010744A (pt)
IL (1) IL210213A (pt)
MX (1) MX2011000081A (pt)
MY (1) MY157197A (pt)
NI (1) NI201000233A (pt)
NZ (2) NZ590169A (pt)
PE (1) PE20140592A1 (pt)
SG (1) SG192446A1 (pt)
SV (1) SV2011003789A (pt)
TW (2) TW201018668A (pt)
UA (1) UA102855C2 (pt)
UY (1) UY31951A (pt)
WO (1) WO2010002777A2 (pt)
ZA (1) ZA201100760B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117399A2 (en) * 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
EP2924025A1 (en) * 2008-06-30 2015-09-30 Janssen Pharmaceutica NV Substituted pyrimidine derivatives
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
MY157197A (en) 2008-06-30 2016-05-13 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
RS59909B1 (sr) * 2013-03-06 2020-03-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora
WO2017076888A1 (en) 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
PL358548A1 (en) * 2000-04-24 2004-08-09 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrate
AU2001289701B2 (en) 2000-07-21 2004-06-24 Syngenta Participations Ag Process for the preparation of 4,6-dimethoxy-2-(methylsulfonyl)-1,3-pyrimidine
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
NZ546259A (en) * 2003-09-30 2009-05-31 Janssen Pharmaceutica Nv Benzoimidazole compounds
JP4767857B2 (ja) * 2003-09-30 2011-09-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ベンゾイミダゾール化合物
MXPA06011021A (es) * 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
KR101260036B1 (ko) * 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
WO2007117399A2 (en) * 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor
ATE479678T1 (de) * 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
MY157197A (en) 2008-06-30 2016-05-13 Janssen Pharmaceutica Nv Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives

Also Published As

Publication number Publication date
US8835633B2 (en) 2014-09-16
IL210213A (en) 2015-08-31
SG192446A1 (en) 2013-08-30
CL2010001639A1 (es) 2011-06-24
US8921550B2 (en) 2014-12-30
WO2010002777A2 (en) 2010-01-07
KR20110022721A (ko) 2011-03-07
MY157197A (en) 2016-05-13
NZ599747A (en) 2013-03-28
EP2865678A2 (en) 2015-04-29
US20100029942A1 (en) 2010-02-04
IL210213A0 (en) 2011-03-31
TW201018668A (en) 2010-05-16
EP2303869A2 (en) 2011-04-06
CR20110057A (es) 2013-01-25
TWI485147B (zh) 2015-05-21
NI201000233A (es) 2011-11-09
PE20140592A1 (es) 2014-05-16
JP2014040426A (ja) 2014-03-06
US20120184740A1 (en) 2012-07-19
NZ590169A (en) 2012-05-25
CA2729703A1 (en) 2010-01-07
CO6341626A2 (es) 2011-11-21
AU2009267159A1 (en) 2010-01-07
ECSP11010744A (es) 2011-02-28
AU2009267159B2 (en) 2014-05-15
UY31951A (es) 2010-01-29
WO2010002777A3 (en) 2010-06-24
CN102137857A (zh) 2011-07-27
US20120178932A1 (en) 2012-07-12
EA020090B1 (ru) 2014-08-29
EP2865678A3 (en) 2015-05-27
ZA201100760B (en) 2012-07-25
JP2011526911A (ja) 2011-10-20
CN103319459A (zh) 2013-09-25
MX2011000081A (es) 2011-03-02
SV2011003789A (es) 2011-04-08
EA201170114A1 (ru) 2011-08-30
UA102855C2 (ru) 2013-08-27
TW201422609A (zh) 2014-06-16
AR072397A1 (es) 2010-08-25

Similar Documents

Publication Publication Date Title
BRPI0918349A2 (pt) Processo para preparar dióxido de divinilareno
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
BRPI0910910A2 (pt) processo para preparar um composto
BRPI0910911A2 (pt) processo para preparar um composto
BRPI0916609A2 (pt) Processo para a preparação de um macrociclo
BRPI0920356A2 (pt) Processo para a preparação de compostos úteis como inibidores de sglt
BRPI0821944A2 (pt) Processo
BRPI0819659A2 (pt) Processo para produção de álcool
PT2121578T (pt) Processo de preparação de ácido 5-bifenil-4-amino-2-metil-pentanoico
BRPI0919868A2 (pt) processo
BRPI0816258A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt
BRPI0911254A2 (pt) processo para a preparação de um composto
BRPI0921374A2 (pt) processo
BRPI0915854A2 (pt) Processo para preparar óxido de etileno
BRPI0921420A2 (pt) processo para preparar compostos
PT2165971T (pt) Processo de hidrotratamento
BRPI0922490A2 (pt) Método para produção de beta-santaleno
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI0919241A8 (pt) processo para fabricação de compostos de quinolona
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI0916360A2 (pt) processo para preparar derivados de ácido r-beta-amino fenilbutírico
BRPI0909004A2 (pt) Processo para produção de biogás
BRPI1008987A2 (pt) processo para preparar 3,3,3-trifluoropropeno
BRPI0912558A2 (pt) Processo para a preparação de amidas
BRPI0917836A2 (pt) processo para preparar uretanos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]